ALIBABA-GROUP
4.8.2022 02:27:08 CEST | Business Wire | Press release
Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988, the “Company”) announces that Irene Yun-Lien Lee, Chairman of Hysan Development Company Limited, and Albert Kong Ping Ng, former Chairman of Ernst & Young China, were appointed as independent directors to the Company’s board, effective August 4, 2022. The new appointments demonstrate the Company’s commitment to corporate governance excellence and diversity at the board level.
Following these appointments, the Company’s board currently consists of twelve directors, including seven independent directors. The number of female board members increases to three.
“I am delighted to welcome Ms. Lee and Mr. Ng to the Alibaba board. The new independent board member appointments are part of Alibaba’s ongoing enhancement of our corporate governance. Irene and Albert are both respected leaders with invaluable understanding and experience in global markets including mainland China and Hong Kong. I believe Alibaba will greatly benefit from their insight, especially in light of our plans for dual-primary listing in Hong Kong to further broaden and diversify our investor base,” said Daniel Zhang, Chairman and Chief Executive Officer of Alibaba Group.
“Alibaba is one of the most exciting and innovative companies of this generation and I am honored to become its board member,” said Irene Yun-Lien Lee. “The focus of my career has been to create a deep connection with consumers by curating top of mind physical destinations, where people come to work, shop and play. I am delighted to join Alibaba, with its mission to make it easier to do business with anyone, anywhere.”
“I am thrilled to join the board of a company with such a distinguished combination of Chinese origin and a global vision,” said Albert Ng. “as Alibaba applies to add Hong Kong as another primary listing venue, I hope my experiences in the capital market of Hong Kong and Greater China can be applied to the company's pursuit of excellence.”
Mr. Chee Hwa Tung, an independent director of the Company, will not seek re-election after his current term, which will end at the Company’s annual shareholding meeting to be held later this year. Mr. Tung has served as an independent director on the Company’s board since September 2014.
“We would like to express our most sincere gratitude to Mr. Tung for his invaluable contributions and full support to Alibaba, which exemplified the highest standards of service and commitment,” said Zhang.
About Irene Lee
Irene Lee has been executive chairman of Hysan Development Company Limited, a company listed on the Hong Kong Stock Exchange, since March 2012. Before that she was Hysan’s non-executive chairman from May 2011 to March 2012, and non-executive director from March 2011 to May 2011. Ms. Lee currently serves as the independent non-executive chairman of Hang Seng Bank Limited, a company listed on the Hong Kong Stock Exchange. She also serves as a director of various private and unlisted companies. Previously, Ms. Lee was an executive director of Citicorp Investment Bank Limited in New York, London and Sydney, and head of corporate finance at Commonwealth Bank of Australia and chief executive officer of Sealcorp Holdings Limited, both based in Sydney. In addition, she was until April 2022 an independent director of HSBC Holdings plc, and also previously served as director of a number of public companies. Ms. Lee received a bachelor of arts degree from Smith College, and is barrister-at-law in England and Wales and a member of the Honourable Society of Gray’s Inn, United Kingdom.
About Albert Ng
Albert Ng currently serves as an independent non-executive director and chairman of the audit committee of a number of public companies, including Ping An Insurance (Group) Company of China, Ltd., a company listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange, Beijing Airdoc Technology Co., Ltd., a company listed on the Hong Kong Stock Exchange, and China International Capital Corporation Limited, a company listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange. Mr. Ng worked at Ernst & Young China from April 2007 to June 2020, where he was the chairman of Ernst & Young China and a member of Ernst & Young’s Global Executive Board. Prior to joining Ernst & Young, he was Greater China Managing Partner of Arthur Andersen, Managing Partner – China Operation of PricewaterhouseCoopers and Managing Director of Citigroup – China Investment Banking. Mr. Ng is the president of the Hong Kong China Chamber of Commerce. Mr. Ng is also a member of the audit committee of The Chinese University of Hong Kong, Shenzhen, and a council member of the Education Foundation of The Chinese University of Hong Kong, Shenzhen. Mr. Ng is a member of the Hong Kong Institute of Certified Public Accountants (HKICPA), Chartered Accountants of Australia and New Zealand (CAANZ), CPA Australia (CPAA) and Association of Chartered Certified Accountants (ACCA). He received a bachelor’s degree in business administration and a master’s degree in business administration from The Chinese University of Hong Kong.
About Alibaba Group
Alibaba Group’s mission is to make it easy to do business anywhere. The company aims to build the future infrastructure of commerce. It envisions that its customers will meet, work and live at Alibaba, and that it will be a good company that lasts for 102 years.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803006055/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer1.9.2026 08:30:00 CEST | Press release
Approval based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years Second approval for Enhertu in the EU in two months Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results fro
Paris Hilton Returns as the Face of KARL LAGERFELD as NOT-KARL Debuts for Fall–Winter 20261.9.2026 08:30:00 CEST | Press release
Following the success of the Maison's Fall-Winter 2025 and Spring-Summer 2026 campaigns, KARL LAGERFELD is delighted to announce the extension of its relationship with global entrepreneur, media personality and cultural icon Paris Hilton, continuing a partnership that has resonated with audiences around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831566835/en/ KARL LAGERFELD - Paris Hilton ©Matt Easton As the face of the Maison through Fall-Winter 2026 and Spring-Summer 2027, Paris Hilton returns for the next chapter of KARL LAGERFELD's From Paris With Love story, continuing to bring her signature confidence, wit and individuality. Photographed for the first time by Matt Easton, the Fall-Winter 2026 campaign introduces a new dimension to the narrative while remaining true to the House's established codes. At the heart of the Fall-Winter 2026 story, two masters of self-reinvention meet. Making his debut is NO
Flashnet Partners with Netmore in Strategic Global Partnership for Smart Street Lighting1.9.2026 08:00:00 CEST | Press release
Collaboration combines carrier-grade LoRaWAN® connectivity with award-winning smart street lighting technology to accelerate smart city transformation Netmore Group, the leading network operator and platform provider for Massive IoT, today announced that Flashnet, a Lucy Group company and global leader in intelligent street lighting solutions, has joined Netmore's Pulse Partner Program. The partnership marks another important milestone in Netmore's growing ecosystem, combining best-in-class connectivity with proven smart infrastructure solutions to accelerate the digital transformation of cities and utilities around the world. Driven by rapid urbanisation, government sustainability mandates, and the accelerating rollout of smart city programs worldwide, smart street lighting is increasingly recognized as the entry point for smart city transformation and one of the fastest-growing segments of the global IoT infrastructure market. As municipalities and utilities continue to modernize cri
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom